Metallus Receives $3.5 Million in Grants from JobsOhio in Support of Planned Expansion of its Steelmaking Plants in Canton
Prnewswire· 2024-08-08 04:10
• Lt. Governor Jon Husted and other officials attended today's groundbreaking ceremony CANTON, Ohio, Aug. 7, 2024 /PRNewswire/ -- Metallus (NYSE: MTUS), a leader in high-quality specialty metals, manufactured components and supply chain solutions, announced today that it has received $3.5 million in grants from JobsOhio to support the planned expansion of its steelmaking plants. Metallus, formerly known as TimkenSteel, plans to invest more than $100 million in partnership with the U.S. Department of Defense ...
RCI to Host 3Q24 Conference Call on X Spaces Exclusively on Thursday, August 8
Prnewswire· 2024-08-08 04:10
公司概况 - 公司是成人夜总会和运动酒吧/餐厅领域的领先企业,在全国拥有60多家门店 [2] 行业概况 - 公司从事成人娱乐和餐厅业务,受到相关法律法规、竞争以及关键人员依赖等因素的影响 [3] - 公司业务受到城市经营环境、新业务开拓成功与否、网络安全、房地产交易条件以及新冠疫情等因素的影响 [3]
Star Bulk Announces Changes To Its Board Of Directors
Newsfilter· 2024-08-08 04:10
ATHENS, Greece, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Star Bulk Carriers Corp. (the "Company" or "Star Bulk") (NASDAQ:SBLK), a global shipping company focusing on the transportation of dry bulk cargoes, announced today the resignation of Mr. Sherman Lau, a Class B Director since May 2021. Ms. Milena Maria Pappas has been appointed by the Board, as Class B Director, to fill the seat made vacant by the resignation of Mr. Lau. The Board currently consists of ten directors. Petros Pappas, Chief Executive Officer of ...
Profire Energy Reports Financial Results for Second Quarter 2024
Newsfilter· 2024-08-08 04:10
LINDON, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Profire Energy, Inc. (NASDAQ:PFIE), a technology company (the "Company") that provides solutions which enhance the efficiency, safety, and reliability of industrial combustion appliances, today reported financial results for its second quarter ending June 30, 2024. A conference call will be held on Thursday, August 8, 2024 at 8:30 a.m. ET to discuss the results. Second Quarter Summary (comparisons to prior-year quarter) Revenue of $15.2 million, compared to $1 ...
ACV Announces Participation in Upcoming Investor Conferences
Newsfilter· 2024-08-08 04:06
文章核心观点 公司宣布管理团队将出席三场投资者会议 [1] 公司概况 - 公司是一家领先的数字化汽车市场和数据服务合作伙伴,为经销商和商业客户提供服务 [3][4] - 公司提供的产品和服务包括ACV Auctions、ACV Transportation、ACV Capital、ACV MAX、True360和ClearCar [4] - 公司致力于通过构建最值得信赖和高效的数字化市场以及数据解决方案,来转变汽车行业 [3] 会议信息 - 公司管理团队将出席以下三场投资者会议: - Canaccord Genuity 44th Annual Growth Conference,时间为2024年8月13日下午4点ET [1] - Citi 2024 Global TMT Conference,时间为2024年9月4日下午4:40 ET [1] - Goldman Sachs Communacopia + Technology Conference,时间为2024年9月10日下午3:45 PT [1] - 这些会议的网络直播将在公司投资者关系网站上提供 [2]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
Newsfilter· 2024-08-08 04:05
PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024. The Company is planning to host a conference call the next morning, Wednesd ...
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
Newsfilter· 2024-08-08 04:05
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RASaddicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The com ...
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
Newsfilter· 2024-08-08 04:02
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as Planned with Ten Community and Academic Sites Opened to Date Across the USEnrollment Completion Expected in 1H 2026 and Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Investigational New Drug (IND) Application for Next-Generation CD19/CD70 Dual CAR with Dagger® Techn ...
MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended June 30, 2024
Newsfilter· 2024-08-08 04:01
Results for the Quarter Ended June 30, 2024 and Other Recent Highlights: ___________________ Net investment income per share for the quarter was $0.45, compared to $0.44 for the quarter ended March 31, 2024 Net asset value per share as of the end of the quarter was $15.38, compared to $15.42 as of March 31, 2024 New investment commitments made during the quarter totaled $285 million(1) Gross fundings, excluding revolver fundings(2), totaled $214 million for the quarter Net fundings, including revolvers(2), ...
NV5 Announces Second Quarter Results and Raises Guidance
Newsfilter· 2024-08-08 04:01
HOLLYWOOD, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (Nasdaq GS: NVEE) ("NV5" or the "Company"), a provider of technology, conformity assessment, consulting solutions, and software applications, today reported financial results for the second quarter ended June 29, 2024. "NV5 continued to build upon its positive momentum in the second quarter, delivering strong organic growth and profitability. We are well-positioned to meet the expected increase in demand for our services in the second half ...